(103 days)
No
The device description and performance studies focus on biological processes (larval debridement) and the impact of a dietary change on the larvae's performance, with no mention of computational algorithms, AI, or ML.
Yes
The "Intended Use / Indications for Use" section explicitly states that these products are "indicated for debridement of non-healing necrotic skin and soft tissue wounds," which describes a therapeutic purpose.
No
This device is indicated for debridement of non-healing necrotic skin and soft tissue wounds, which is a therapeutic function, not a diagnostic one.
No
The device description explicitly states the product consists of "live larvae" and describes their physical form and packaging. This is a biological product, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the debridement of non-healing necrotic skin and soft tissue wounds. This is a therapeutic application, not a diagnostic one. IVDs are used to examine specimens from the human body to provide information for diagnosis, monitoring, or screening.
- Device Description: The device consists of live larvae applied directly to a wound. This is a biological therapy, not a test performed on a sample outside the body.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples, detecting analytes, or providing diagnostic information.
The device is a therapeutic device used for wound debridement.
N/A
Intended Use / Indications for Use
The BioMonde Larval Debridement Therapy Products - Larvae 100/200/300 are indicated for debridement of non-healing necrotic skin and soft tissue wounds, including pressure ulcers, neuropathic foot ulcers, and non-healing traumatic or post-surgical wounds.
The BioMonde Larval Debridement Therapy Products - BioBag 50/100/200/300/400 are indicated for debridement of non-healing necrotic skin and soft tissue wounds, including pressure ulcers, neuropathic foot ulcers, and non-healing traumatic or post-surgical wounds.
Product codes
NQK
Device Description
The BioMonde Larval Debridement Therapy Products - Larvae 100/200/300 and BioMonde BioBag 50/100/200/300/400 products are live larvae, stage I and II, of the green bottle fly Lucilia sericata, provided either loose or within a sterile bag, respectively. The larvae are derived from disinfected fly eggs. Larvae are transferred under controlled manufacturing conditions into sterilized transport tubes or sterilized bags which are then placed into sterile transport tubes. These tubes are additionally pouched and boxed for transport. Upon arrival at the treatment location, they are applied to the wound and covered with permeable and absorbent dressings (not provided).
The modification to these products consists of replacing the feed used for stock flies from liver to a special mixture of nutrients called the "Carnival Diet". The Carnival Diet is also used to rear new fly generations and as a medium to induce egg laying. The reason for changing to this feeding material is to reduce the risk of transmission of viruses by removing the use of unprocessed animal organs and change to using pharmaceutical-grade animal-derived material.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
skin and soft tissue wounds
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Study type: Non-clinical performance testing.
Sample size: Not specified.
AUC: Not applicable.
MRMC: Not applicable.
Standalone performance: Not applicable.
Key results: Bench testing demonstrated that the product, as modified by changing the feed of the stock flies from liver to the "Carnival Diet," fulfills the same design and performance specifications as the cleared predicate devices. Non-clinical testing of stock flies and larvae showed that flies and larvae reared with the Carnival Diet appear slightly smaller but are as healthy and effective in terms of debridement activity as those derived from flies reared on liver. No difference in enzyme patterns was found. Testing across generations indicated that adaptation to the Carnival Diet over at least 3 generations is necessary for satisfactory performance.
Key Metrics
Not Found
Predicate Device(s)
BioMonde Larval Debridement Therapy Products Larvae 100/200/300 (K123449), BioMonde BioBag 50/100/200/300/400 (K131221)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
N/A
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features the department's name in a circular arrangement around a symbol. The symbol consists of a stylized depiction of three human profiles facing to the right. The profiles are stacked on top of each other, creating a sense of depth and unity.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
November 5, 2014
BioMonde Ms. Rosina Robinson, RN, MEd, RAC Aptiv Solutions 62 Forest Street, Suite 300 Marlborough, Massachusetts 01752
Re: K142020
Trade/Device Name: BIOMONDE LARVAL DEBRIDEMENT THERAPY PRODUCTS, LARVAE 100/200/300 AND BIOBAG 50/100/200/300/400 Regulatory Class: Unclassified Product Code: NQK Dated: October 15, 2014 Received: October 16, 2014
Dear Ms. Robinson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
1
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
David Krause -S
Binita S. Ashar, M.D., M.B.A., F.A.C.S. for Director
Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K142020
Device Name
BIOMONDE LARVAL DEBRIDEMENT THERAPY PRODUCTS, LARVAE 100/200/300 AND BIOBAG 50/100/200/300/400
Indications for Use (Describe)
The BioMonde Larval Debridement Therapy Products - Larvae 100/200/300 are indicated for debridement of non-healing necrotic skin and soft tissue wounds, including pressure ulcers, neuropathic foot ulcers, and nonhealing traumatic or post-surgical wounds.
The BioMonde Larval Debridement Therapy Products - BioBag 50/100/200/300/400 are indicated for debridement of non-healing necrotic skin and soft tissue wounds, including pressure ulcers, neuropathic foot ulcers, and non-healing traumatic or post-surgical wounds.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| Prescription Use (Part 21 CFR 801 Subpart D) | |
| Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
5. 510(K) SUMMARY
BIOMONDE LARVAL DEBRIDEMENT THERAPY PRODUCTS LARVAE 100/200/300 AND BIOBAG 50/100/200/300/400 (PER 21CFR 807.92)
1. SUBMITTER/510(K) HOLDER
BioMonde (a trading name of ZooBiotic Limited) Units 2-4 Dunraven Business Park Coychurch Road Bridgend CF31 3BG United Kingdom Contact Person: Suzanne Morgan
| Telephone: | Office (UK): +44 (0)845 230 1810; |
|---|---|
| Office (Germany): +49 (0)40 6710 570 |
Date Prepared: November 4, 2014
2. DEVICE NAME
| Proprietary Name: | Larval Debridement Therapy Products – Larvae 100/200/300 and
BioBag 50/100/200/300/400 |
|----------------------|-------------------------------------------------------------------------------------------|
| Common/Usual Name: | Larval debridement therapy products |
| Classification Name: | Unclassified |
3. PREDICATE DEVICES
- · BioMonde Larval Debridement Therapy Products Larvae 100/200/300 (K123449)
- · BioMonde BioBag 50/100/200/300/400 (K131221)
4. DEVICE DESCRIPTION
The BioMonde Larval Debridement Therapy Products - Larvae 100/200/300 and BioMonde BioBag 50/100/200/300/400 products are live larvae, stage I and II, of the green bottle fly Lucilia sericata, provided either loose or within a sterile bag, respectively. The larvae are derived from disinfected fly eggs. Larvae are transferred under controlled manufacturing conditions into sterilized transport tubes or sterilized bags which are then placed into sterile transport tubes. These tubes are additionally pouched and boxed for transport. Upon arrival at the treatment location, they are applied to the wound and covered with permeable and absorbent dressings (not provided).
4
The modification to these products consists of replacing the feed used for stock flies from liver to a special mixture of nutrients called the "Carnival Diet". The Carnival Diet is also used to rear new fly generations and as a medium to induce egg laying. The reason for changing to this feeding material is to reduce the risk of transmission of viruses by removing the use of unprocessed animal organs and change to using pharmaceutical-grade animal-derived material.
5. INDICATION FOR USE/INTENDED USE
The BioMonde Larval Debridement Therapy Products - Larvae 100/200/300 are indicated for debridement of non-healing necrotic skin and soft tissue wounds, including pressure ulcers, venous stasis ulcers, neuropathic foot ulcers, and non-healing traumatic or postsurgical wounds.
The BioMonde Larval Debridement Therapy Products - BioBag 50/100/200/300/400 are indicated for debridement of non-healing necrotic skin and soft tissue wounds, including pressure ulcers, venous stasis ulcers, neuropathic foot ulcers, and non-healing traumatic or post-surgical wounds.
6. SUMMARY OF TECHNOLOGICAL CHARACTERISTICS COMPARED TO THE PREDICATE DEVICE/S
The technological characteristics of the modified BioMonde Larval Debridement Therapy Products are unchanged from that of the cleared parent devices with the sole difference being that flies raised on the Carnival Diet do not lay their eggs on liver.
5
Side-by-Side Comparison of the Technological Characteristics of the Modified and Parent BioMonde Larval Debridement Therapy Products (Larvae 100/200/300 and BioBag 50/100/200/300/400)
| | Modified BioMonde
Larval Debridement
Therapy Products | Parent | | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|----------------------------------|-----------------------------------------|--|--|
| Characteristic | | LARVAE
100/200/300
K123449 | BIOBAG
50/100/200/300/400
K131221 | | |
| Fundamental Technological Characteristics | | | | | |
| Lucilia sericata/Phaenecia sericata from a closed, monitored colony | Yes | Yes | Yes | | |
| Oviposition takes place on liver obtained from an approved supplier of
animal tissue. Eggs are carefully removed from the liver and weighed. | No | Yes | Yes | | |
| Collected eggs are separated using sodium sulfite solution and mechanical
agitation prior to sieving to ensure only single eggs enter the disinfection
process. | Yes | Yes | Yes | | |
| Eggs are disinfected in a two stage process using 7.2% formaldehyde
solution and 3.9% peracetic acid solution, after which they are rinsed with
sterile sodium chloride 0.9%. | Yes | Yes | Yes | | |
| Disinfected eggs are inoculated onto the surface of a defined growth
medium (Lucilia agar) contained in 90mm petri dishes. The petri dishes
are placed into an incubator for 20-24 hours at 31-35°C where the eggs
hatch and the larvae reach 2-6mm in size. | Yes | Yes | Yes | | |
| Available in containers of varying numbers of larvae | Yes | Yes | Yes | | |
| Larvae are removed from the growth medium using a loop or spoon and
placed into containers marked with fill heights for the dosage required. | Yes | Yes | Yes | | |
| The correct dosage of larvae is transferred to a sterile transport tube. | Same as parent devices | Yes | No | | |
| The transport tubes containing the larvae are labeled, the tube is placed into
a pouch which is labeled and the pouch is placed into a labeled transport
box with the instructions for use. | Yes | Yes | Yes | | |
6
7. SUMMARY OF NON-CLINICAL PERFORMANCE TESTING AS BASIS FOR SUBSTANTIAL EQUIVALENCE
This Premarket Notification presents bench testing that demonstrates that the product, as modified by changing the feed of the stock flies from liver to the special mixture of nutrients called the "Carnival Diet" fulfills the same design and performance specifications disclosed in the cleared 510(k)s for the BioMonde Larvae 100/300/300 and BioBag 50/100/200/300/400.
Non-clinical testing of stock flies and larvae was performed to demonstrate the substantial equivalence of design and performance of flies and larvae reared with liver (predicate control) and flies and larvae reared with the Carnival Diet (proposed modified product). Testing consisted of the following:
-
- Monitoring of the 4 descriptive parameters for fly colony health & fitness (larval duration, pupae weight, pupae hatch success and egg vield); and
-
- Performance of the Larval Activity Assay (consumption of protein by a set number of the larvae over a 2-day period in a defined apparatus) and enzyme pattern of larval secretions.
The results obtained using the Carnival Diet for five (5) generations were compared with those observed with flies and larvae fed with liver (control). The comparative testing demonstrates that the flies and larvae reared with Carnival Diet appear to be slightly smaller in size but are as healthy and effective in terms of debridement activity as those derived from flies reared on liver. No difference in enzyme patterns was found between the control and the Carnival Diet groups. Testing across generations indicates that adaptation to the Carnival Diet over at least 3 generations is necessary to assure satisfactory performance.
When the proposed product is compared to flies and larvae of the two predicate devices, the proposed product is substantially equivalent in performance.
8. SUMMARY OF CLINICAL TESTING AS BASIS FOR SUBSTANTIAL EQUIVALENCE
No clinical data were included in this Traditional 510(k) Premarket Notification.
9. SUMMARY OF OTHER INFORMATION
Other information provided in this Traditional 510(k) Premarket Notification includes manufacturing information which is fundamentally unchanged from that of the cleared devices.
7
10. CONCLUSIONS DRAWN FROM NON-CLINICAL AND CLINICAL TESTS
Based on the information provided in this Traditional 510(k) Premarket Notification, BioMonde has determined that the products as modified are substantially equivalent, that differences are minor, and do not raise new safety and effectiveness questions.